SPONSORED SYMPOSIUM
Delirium Should "Never" Occur. But If It Does...
Supported by an educational grant from Hospira
Release date: March 2010
Expiration date: March 2011
Estimated running time: 1.5 hours
AGENDA
Moderator: John W. Devlin, PharmD, FCCM, BCPS
Delirium as the Next Proposed "Never" Event: Is This Realistic?
Pratik P. Pandharipande, MD, FCCM
Haloperidol: The "Go-To" Drug. Are Atypicals a Better Option?
John W. Devlin, PharmD, FCCM, BCPS
Haloperidol: The "Go-To" Drug. Is Dexmedetomidine a Better Option?
Richard R. Riker, MD
Click here to begin viewing - Requirements for viewing media
LEARNING OBJECTIVES
1. Review the risk factors for delirium
2. Discuss the role of dexmedetomidine in the treatment of delirium
3. Discuss the role of atypicals in the treatment of delirium
SPEAKER DISCLOSURES
Faculty have reported the following disclosures. A copy of SCCM’s policy on resolving conflicts of interest can be found online
John W. Devlin, PharmD, FCCM, BCPS
Northeastern University
Boston, MA, USA
Research Grant - AstraZeneca
Pratik P. Pandharipande, MD, FCCM
Vanderbilt University Medical Center
Nashville, TN, USA
Honorarium, research grant - Hospira Inc, makers of Dexmedetomidine
Richard R. Riker, MD
Maine Medical Center
Portland, ME, USA
Research Grant Support-Aspect Medical Systems on Outcome Prediction after Cardiac Arrest
CONTINUING EDUCATION
This activity includes text, graphics, and may include multi-media features. There are no fees for participating in or receiving credit for this activity. Click on the arrow in the video screen to your right to review the content presented. You must view all of the content to proceed to the evaluation.
Participants must respond to all evaluation questions to receive a letter of credit. Once the evaluation is completed, SCCM will review your application and email your certificate within 14 days of receipt. For questions, please contact education@sccm.org or call +1 847-827-6869.
To complete the evaluation and obtain continuing education, please click here.
Type of activity
This activity was designed as an evidenced-based forum to review expert opinions of Delirium. This activity will focus on increasing knowledge and its application to practice.
Competencies
SCCM supports recommendations that will promote life long learning through continuing education. SCCM promotes activities that encourage the highest quality in education that will enhance knowledge, competence or performance in critical care practice. This activity will meet the following:
-Patient and Family Centered Care
-Practice Applications
-Quality Improvement
-Multiprofessionalism
Target Audience
This continuing medical education offering is intended to meet the needs of all physicians, nurses, pharmacists, respiratory therapists and other providers who care for critically ill patients.
Physicians
Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education by Society of Critical Care Medicine (SCCM). SCCM is accredited by ACCME to provide continuing medical education for physicians.
Designation Statement
The Society of Critical Care Medicine designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim credit commensurate with the extent of their participation in the activity.
Nurses
SCCM is approved by the California Board of Registered Nursing, Provider No. 8181 and approves this panel for 1.5 contact hours.
Pharmacists
The Society of Critical Care Medicine is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmaceutical education. This Panel Discussion will provide 1.5 continuing education hours. (0236-0000-10-222-H01-P)
Privacy Policy
To view a copy of the Society’s privacy policy, please click here.
